Definitions and mechanisms of drug hypersensitivity

References

• Aberer W, Bircher A, Romano A et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy58(9), 854–863 (2003).
   PubMed Web of Science ®Google Scholar
• Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet356(9237), 1255–1259 (2000).
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ329(7456), 15–19 (2004).
   PubMed Web of Science ®Google Scholar
• Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch. Intern. Med.167(16), 1752–1759 (2007).
   PubMed Web of Science ®Google Scholar
• Aronson JK, Ferner RE. Joining the DoTS: new approach to classifiying adverse drug reactions. BMJ327, 1222–1225 (2003).
   PubMedGoogle Scholar
• Ferner RE, Aronson JK. EIDOS: a mechanistic classification of adverse drug effects. Drug Saf.33(1), 1–8 (2010).
   PubMedGoogle Scholar
• Johansson SG, Hourihane JO, Bousquet J et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy56, 813–824 (2001).
   PubMed Web of Science ®Google Scholar
• Justiniano H, Berlingeri-Ramos AC, Sanchez JL. Pattern analysis of drug-induced skin diseases. Am. J. Dermatopathol.30(4), 352–369 (2008).
   PubMed Web of Science ®Google Scholar
• Bousquet PJ, Kvedariene V, Co-Minh HB et al. Clinical presentation and time course in hypersensitivity reactions to β-lactams. Allergy62(8), 872–876 (2007).
   PubMedGoogle Scholar
• Blanca M, Romano A, Torres MJ et al. Update on the evaluation of hypersensitivity reactions to β lactams. Allergy64(2), 183–193 (2009).
   PubMed Web of Science ®Google Scholar
• Torres MJ, Blanca M, Fernandez J et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy58(10), 961–972 (2003).
   PubMed Web of Science ®Google Scholar
• Schmid DA, Campi P, Pichler WJ. Hypersensitivity reactions to quinolones. Curr. Pharm. Des.12(26), 3313–3326 (2006).
   PubMed Web of Science ®Google Scholar
• Manfredi M, Severino M, Testi S et al. Detection of specific IgE to quinolones. J. Allergy Clin. Immunol.113(1), 155–160 (2004).
   PubMed Web of Science ®Google Scholar
• Heinzerling L, Raile K, Rochlitz H, Zuberbier T, Worm M. Insulin allergy: clinical manifestations and management strategies. Allergy63(2), 148–155 (2008).
   PubMedGoogle Scholar
• Jappe U. Allergy to heparins and anticoagulants with a similar pharmacological profile: an update. Blood Coagul. Fibrinolysis17(8), 605–613 (2006).
   PubMed Web of Science ®Google Scholar
• Mertes PM, Imone-Gastin I, Gueant-Rodriguez RM et al. Hypersensitivity reactions to neuromuscular blocking agents. Curr. Pharm. Des.14(27), 2809–2825 (2008).
   PubMedGoogle Scholar
• Romano A, Blanca M, Torres MJ et al. Diagnosis of nonimmediate reactions to β-lactam-antibiotics. Allergy59, 1153–1160 (2004).
   PubMed Web of Science ®Google Scholar
• Pichler WJ, Yawalkar N, Britschgi M et al. Cellular and molecular pathophysiology of cutaneous drug reactions. Am. J. Clin. Dermatol.3(4), 229–238 (2002).
   PubMedGoogle Scholar
• Pichler W, Yawalkar N, Schmid S, Helbling A. Pathogenesis of drug-induced exanthems. Allergy57(10), 884–893 (2002).
   PubMed Web of Science ®Google Scholar
• Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions – new concepts. Clin. Exp. Allergy37(7), 989–999 (2007).
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science296(5566), 301–305 (2002).
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Naisbitt DJ, Gordon F, Park BK. The danger hypothesis – potential role in idiosyncratic drug reactions. Toxicology181–182, 55–63 (2002).
   PubMed Web of Science ®Google Scholar
• Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann. Intern. Med.146(9), 657–665 (2007).
   PubMed Web of Science ®Google Scholar
• Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum. Psychopharmacol.23(Suppl. 1), 27–41 (2008).
   PubMed Web of Science ®Google Scholar
• Williams DP, Kitteringham NR, Naisbitt DJ, Pirmohamed M, Smith DA, Park BK. Are chemically reactive metabolites responsible for adverse reactions to drugs? Curr. Drug Metab.3(4), 351–366 (2002).
   PubMedGoogle Scholar
• Gao Y, Zhao MH. Review article: drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton)14(1), 33–41 (2009).
   PubMed Web of Science ®Google Scholar
• Wiik A. Drug-induced vasculitis. Curr. Opin. Rheumatol.20(1), 35–39 (2008).
   PubMed Web of Science ®Google Scholar
• Merkel PA. Drug-induced vasculitis. Rheum. Dis. Clin. North Am.27(4), 849–862 (2001).
   PubMed Web of Science ®Google Scholar
• Hari Y, Frutig-Schnyder K, Hurni M et al. T cell involvement in cutaneous drug eruptions. Clin. Exp. Allergy31(9), 1398–1408 (2001).
   PubMed Web of Science ®Google Scholar
• Barbaud A. Drug patch tests in the investigation of cutaneous adverse drug reactions. Ann. Dermatol. Venereol.136(8–9), 635–644 (2009).
   PubMedGoogle Scholar
• Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology209(2), 209–216 (2005).
   PubMed Web of Science ®Google Scholar
• Lochmatter P, Zawodniak A, Pichler WJ. In vitro tests in drug hypersensitivity diagnosis. Immunol. Allergy Clin. North Am.29(3), 537–554 (2009).
   PubMed Web of Science ®Google Scholar
• Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin. Exp. Allergy27(2), 175–181 (1997).
   PubMed Web of Science ®Google Scholar
• Martin M, Wurpts G, Ott H et al.In vitro detection and characterization of drug hypersensitivity using flow cytometry. Allergy65(1), 32–39 (2009).
   PubMedGoogle Scholar
• Zawodniak A, Lochmatter P, Yerly D et al.In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. Allergy65(3), 376–384 (2009).
   PubMedGoogle Scholar
• Fernandez TD, Canto G, Blanca M. Molecular mechanisms of maculopapular exanthema. Curr. Opin. Infect. Dis.22(3), 272–278 (2009).
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J. Dtsch Dermatol. Ges.7(2), 142–160 (2009).
   PubMedGoogle Scholar
• Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N. Engl. J. Med.331(19), 1272–1285 (1994).
   PubMed Web of Science ®Google Scholar
• Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann. Allergy Asthma Immunol.94(4), 419–436 (2005).
   PubMed Web of Science ®Google Scholar
• Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J. Am. Acad. Dermatol.56(2), 181–200 (2007).
   PubMed Web of Science ®Google Scholar
• Carr DR, Houshmand E, Heffernan MP. Approach to the acute, generalized, blistering patient. Semin. Cutan. Med. Surg.26(3), 139–146 (2007).
   PubMedGoogle Scholar
• Levi N, Bastuji-Garin S, Mockenhaupt M et al. Medications as risk factors of Stevens–Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics123(2), E297–E304 (2009).
   PubMed Web of Science ®Google Scholar
• Struck MF, Hilbert P, Mockenhaupt M, Reichelt B, Steen M. Severe cutaneous adverse reactions: emergency approach to non-βurn epidermolytic syndromes. Intensive Care Med.36(1), 22–32 (2009).
   PubMedGoogle Scholar
• Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J. Am. Acad. Dermatol.58(1), 33–40 (2008).
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M, Viboud C, Dunant A et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J. Invest. Dermatol.128(1), 35–44 (2008).
   PubMed Web of Science ®Google Scholar
• Barreiro P, Soriano V, Casas E et al. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS14(14), 2153–2157 (2000).
   PubMed Web of Science ®Google Scholar
• Halevy S, Ghislain PD, Mockenhaupt M et al. Allopurinol is the most common cause of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J. Am. Acad. Dermatol.58(1), 25–32 (2008).
   PubMed Web of Science ®Google Scholar
• Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine and toxic epidermal necrolysis. Lancet348(9041), 1597 (1996).
   PubMedGoogle Scholar
• Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br. J. Dermatol.68, 355–361 (1956).
   PubMed Web of Science ®Google Scholar
• Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N. Engl. J. Med.355(17), 1800–1810 (2006).
   PubMed Web of Science ®Google Scholar
• Correia O, Delgado L, Barbosa IL et al. CD8+ lymphocytes in the blister fluid of severe acute cutaneous graft-versus-host disease: further similarities with toxic epidermal necrolysis. Dermatology203(3), 212–216 (2001).
   PubMedGoogle Scholar
• Quinn AM, Brown K, Bonish BK et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch. Dermatol.141(6), 683–687 (2005).
   PubMedGoogle Scholar
• Correia O, Delgado L, Ramos JP, Resende C, Torrinha JA. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch. Dermatol.129(4), 466–468 (1993).
   PubMedGoogle Scholar
• Nassif A, Bensussan A, Boumsell L et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol.114(5), 1209–1215 (2004).
   PubMed Web of Science ®Google Scholar
• Lonjou C, Thomas L, Borot N et al. A marker for Stevens–Johnson syndrome ethnicity matters. Pharmacogenomics J.6(4), 265–268 (2006).
   PubMed Web of Science ®Google Scholar
• Lonjou C, Borot N, Sekula P et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics18(2), 99–107 (2008).
   PubMed Web of Science ®Google Scholar
• Hung SI, Chung WH, Liou LB et al.HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA102(11), 4134–4139 (2005).
   PubMed Web of Science ®Google Scholar
• Correia O, Delgado L, Roujeau JC, Le CL, Fleming-Torrinha JA. Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch. Dermatol.138(1), 29–32 (2002).
   PubMedGoogle Scholar
• Wolkenstein P, Charue D, Laurent P, Revuz J, Roujeau JC, Bagot M. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch. Dermatol.131(5), 544–551 (1995).
   PubMed Web of Science ®Google Scholar
• Miyauchi H, Hosokawa H, Akaeda T, Iba H, Asada Y. T-cell subsets in drug-induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CD8-positive T cells. Arch. Dermatol.127(6), 851–855 (1991).
   PubMedGoogle Scholar
• Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science282, 490–493 (1998).
   PubMed Web of Science ®Google Scholar
• Abe R. Toxic epidermal necrolysis and Stevens–Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases. J. Dermatol. Sci.52(3), 151–159 (2008).
   PubMed Web of Science ®Google Scholar
• Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J. Allergy Clin. Immunol.122(5), 992–1000 (2008).
   PubMed Web of Science ®Google Scholar
• Ueta M, Sotozono C, Inatomi T, Kojima K, Hamuro J, Kinoshita S. Association of Fas Ligand gene polymorphism with Stevens–Johnson syndrome. Br. J. Ophthalmol.92(7), 989–991 (2008).
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ. Saving the skin from drug-induced detachment. Nat. Med.14(12), 1311–1313 (2008).
   PubMed Web of Science ®Google Scholar
• Chung WH, Hung SI, Yang JY et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens–Johnson syndrome and toxic epidermal necrolysis. Nat. Med.14(12), 1343–1350 (2008).
   PubMed Web of Science ®Google Scholar
• Verneuil L, Ratajczak P, Allabert C et al. Endothelial cell apoptosis in severe drug-induced bullous eruptions. Br. J. Dermatol.161(6), 1371–1375 (2009).
   PubMedGoogle Scholar
• Knowles SR, Shear NH. Recognition and management of severe cutaneous drug reactions. Dermatol. Clin.25(2), 245–253, VIII (2007).
   PubMed Web of Science ®Google Scholar
• Chan HL. Observations on drug-induced toxic epidermal necrolysis in Singapore. J. Am. Acad. Dermatol.10(6), 973–978 (1984).
   PubMedGoogle Scholar
• Valeyrie-Allanore L, Poulalhon N, Fagot JP et al. Stevens–Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. Radiother. Oncol.87(2), 300–303 (2008).
   PubMedGoogle Scholar
• Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch. Dermatol.138(8), 1019–1024 (2002).
   PubMed Web of Science ®Google Scholar
• Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun. Rev.5(2), 160–164 (2006).
   PubMedGoogle Scholar
• Mandelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus? J. Am. Acad. Dermatol.48(4), 525–529 (2003).
   PubMedGoogle Scholar
• Wanat KA, Anadkat MJ, Klekotka PA. Seasonal variation of Stevens–Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim–sulfamethoxazole. J. Am. Acad. Dermatol.60(4), 589–594 (2009).
   PubMed Web of Science ®Google Scholar
• Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP) – a clinical reaction pattern. J. Cutan. Pathol.28(3), 113–119 (2001).
   PubMed Web of Science ®Google Scholar
• Britschgi M, Pichler WJ. Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Curr. Opin. Allergy Clin. Immunol.2(4), 325–331 (2002).
   PubMed Web of Science ®Google Scholar
• Britschgi M, Steiner UC, Schmid S et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J. Clin. Invest.107(11), 1433–1441 (2001).
   PubMed Web of Science ®Google Scholar
• Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin. Liver Dis.6(3), 755–774 (2002).
   PubMedGoogle Scholar
• Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus18(11), 935–940 (2009).
   PubMed Web of Science ®Google Scholar
• Vedove CD, Del GM, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch. Dermatol. Res.301(1), 99–105 (2009).
   PubMed Web of Science ®Google Scholar
• Brockow K, Romano A, Aberer W et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media – a European multicenter study. Allergy64(2), 234–241 (2009).
   PubMed Web of Science ®Google Scholar
• Brockow K, Christiansen C, Kanny G et al. Management of hypersensitivity reactions to iodinated contrast media. Allergy60(2), 150–158 (2005).
   PubMed Web of Science ®Google Scholar
• Brockow K. Immediate and delayed reactions to radiocontrast media: is there an allergic mechanism? Immunol. Allergy Clin. North Am.29(3), 453–468 (2009).
   PubMedGoogle Scholar
• Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J. Allergy Clin. Immunol.111(5), 913–921 (2003).
   PubMed Web of Science ®Google Scholar
• Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J. Allergy Clin. Immunol.118(4), 773–786 (2006).
   PubMed Web of Science ®Google Scholar
• Grattan CE. Aspirin sensitivity and urticaria. Clin. Exp. Dermatol.28(2), 123–127 (2003).
   PubMed Web of Science ®Google Scholar
• Sczczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur. Respir. J.3, 588–593 (1990).
   PubMedGoogle Scholar
• De Weck AL, Sanz ML, Gamboa PM et al. Nonsteroidal anti-inflammatory drug hypersensitivity syndrome. A multicenter study. I. Clinical findings and in vitro diagnosis. J. Investig. Allergol. Clin. Immunol.19(5), 355–369 (2009).
   PubMedGoogle Scholar
• Jenneck C, Juergens U, Buecheler M, Novak N. Pathogenesis, diagnosis, and treatment of aspirin intolerance. Ann. Allergy Asthma Immunol.99(1), 13–21 (2007).
   PubMedGoogle Scholar
• Palikhe NS, Kim SH, Park HS. What do we know about the genetics of aspirin intolerance? J. Clin. Pharm. Ther.33(5), 465–472 (2008).
   PubMedGoogle Scholar
• Himly M, Jahn-Schmid B, Pittertschatscher K et al. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J. Allergy Clin. Immunol.111(4), 882–888 (2003).
   PubMed Web of Science ®Google Scholar
• Kowalski ML, Bienkiewicz B, Woszczek G, Iwaszkiewicz J, Poniatowska M. Diagnosis of pyrazolone drug sensitivity: clinical history versus skin testing and in vitro testing. Allergy Asthma Proc.20(6), 347–352 (1999).
   PubMedGoogle Scholar
• Wedi B, Kapp A. Aspirin induced adverse skin reactions: new pathophysiological aspects. Thorax55, S70–S71 (2000).
   Google Scholar
• Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy62(10), 1111–1118 (2007).
   PubMed Web of Science ®Google Scholar
• Bousquet PJ, Demoly P, Romano A et al. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project. Allergy64(2), 194–203 (2009).
   PubMedGoogle Scholar